Lilly registers Phase 3 of eloralintide-tirzepatide coformulation in type 2 diabetes
The two-year trial will compare EloraTZP against tirzepatide alone for body weight reduction in adults with obesity or overweight and type 2 diabetes.
PR
By Priya Raman · Science Reporter
Oct 19 08:00 ETSource: ClinicalTrials.gov
The wire
- 01Eli Lilly posted NCT07881458, a Phase 3 study of LY900043, an eloralintide and tirzepatide coformulation, with a November 2026 start and about two years of participation.
- 02The amylin-incretin combination tests whether adding an amylin analog beats tirzepatide alone on weight in a diabetes population, a key question for prescribers tracking the next incretin wave.
- 03The listing is not yet recruiting and no enrollment target, dosing or endpoint detail beyond body weight reduction appears in the posted record.
From the source
Read at clinicaltrials.govA Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes
NCT07881458 · PHASE3 · NOT YET RECRUITING · Sponsor: Eli Lilly and Company · Conditions: Obesity, Overweight, Diabetes Mellitus, Type 2.
Source URL https://clinicaltrials.gov/study/NCT07881458
